Immunocore Holdings plc (FRA:6YG)
27.60
-0.20 (-0.72%)
At close: Sep 18, 2026
Immunocore Holdings Revenue
Immunocore Holdings had revenue of $314.85M USD in the twelve months ending June 30, 2026, down -11.60% year-over-year. In the year 2025, Immunocore Holdings had annual revenue of $400.02M with 28.95% growth.
Revenue (ttm)
$314.85M
Revenue Growth
-11.60%
P/S Ratio
3.81
Revenue / Employee
$600.85K
Employees
524
Market Cap
1.44B EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.02M | 89.81M | 28.95% |
| Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
| Dec 31, 2023 | 249.43M | 215.75M | 640.71% |
| Dec 31, 2022 | 33.67M | -2.81M | -7.70% |
| Dec 31, 2021 | 36.48M | -4.69M | -11.39% |
| Dec 31, 2020 | 41.17M | 7.13M | 20.95% |
| Dec 31, 2019 | 34.04M | 3.91M | 12.98% |
| Dec 31, 2018 | 30.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biotest GmbH & Co. KGaA | 648.90M |
| Novogenia AG | 54.30M |
| Paion AG | 14.81M |
| MagForce AG | 1.08M |
| co.don AG | 22.00K |
| Biomark Diagnostics | 17.14K |
| bioXXmed AG | 16.73K |
| 2invest AG | -1.64M |
Immunocore Holdings News
- 5 days ago - Immunocore Holdings Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 days ago - Immunocore achieves target patient enrollment in TEBE-AM clinical trial - TheFly
- 6 days ago - Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma - GlobeNewsWire
- 9 days ago - Immunocore Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 19 days ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 4 weeks ago - Immunocore reinstated with an Overweight at JPMorgan - TheFly
- 6 weeks ago - Immunocore price target raised to $43 from $40 at Morgan Stanley - TheFly
- 6 weeks ago - Immunocore Holdings Earnings Call Transcript: Q2 2026 - Transcripts